Transgene Biotek has entered into a definitive licensing and technology transfer agreement with Atral Cipan of Portugal. The agreement provides the basis for the manufacture, commercialization and marketing of the immune-suppressant drug Tacrolimus using technology developed and transferred by Transgene Biotek. As a result of this agreement, Atral Cipan will move the product through regulatory filings with the US FDA and European Medicines Agency (EMEA) for the manufacturing and marketing of Tacrolimus.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.93 INR | +2.06% |
|
+1.13% | -9.52% |
1st Jan change | Capi. | |
---|---|---|
-9.52% | 7.95M | |
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- TRABI6 Stock
- News Transgene Biotek Limited
- Transgene Biotek Signs Licensing and Technology Transfer Pact with Atral Cipan